UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): January 09, 2025 |
Alector, Inc.
(Exact name of Registrant as Specified in Its Charter)
| | | | |
Delaware | 001-38792 | 82-2933343 |
(State or Other Jurisdiction
of Incorporation) | (Commission File Number) | (IRS Employer
Identification No.) |
| | | | |
131 Oyster Point Blvd. Suite 600 | |
South San Francisco, California | | 94080 |
(Address of Principal Executive Offices) | | (Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: (415) 231-5660 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class
| | Trading
Symbol(s) | |
Name of each exchange on which registered
|
Common Stock | | ALEC | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
Alector, Inc. (the “Company”) was developing AL002, its TREM2 program asset, to treat patients with early Alzheimer’s disease (AD) in collaboration with AbbVie Biotechnology, Ltd. (“AbbVie”) under the Co-Development and Option Agreement, dated as of October 16, 2017, between the parties, as amended on February 13, 2023 (the “AbbVie Agreement”). As announced on November 25, 2024, the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early AD did not meet its primary endpoint. On January 9, 2025, AbbVie provided written notice to the Company terminating the TREM2 program. As that program is the only remaining program under the AbbVie Agreement, such termination also terminates the AbbVie Agreement. The Company and AbbVie have agreed that such termination will be effective 30 days from the receipt of the termination letter.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | | ALECTOR, INC. |
| | | |
Date: | January 10, 2025 | By: | /s/ Marc Grasso |
| | | Marc Grasso, M.D.
Chief Financial Officer |
